Efalizumab: A review of events reported during clinical trials and side effects

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 197-209

  Scheinfeld, Noah ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Biological therapy; Efalizumab; Psoriasis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; ANTIINFECTIVE AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVE VACCINE; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; TERAZOSIN; MONOCLONAL ANTIBODY;

ABSCESS; ACCIDENTAL INJURY; ACNE; ANGIONEUROTIC EDEMA; ARTHRALGIA; ASEPTIC MENINGITIS; ASTHENIA; ASTHMA; BACKACHE; BACTERIAL ARTHRITIS; BASAL CELL CARCINOMA; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CELLULITIS; CHILD CARE; CHILL; CLINICAL TRIAL; CONJUNCTIVITIS; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; EOSINOPHILIA; EXTERNAL OTITIS; FLU LIKE SYNDROME; GASTROENTERITIS; GENOTOXICITY; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HODGKIN DISEASE; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARYNX SPASM; LEGIONNAIRE DISEASE; LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYALGIA; MYCOSIS; MYELITIS; NAUSEA; NECROTIZING FASCIITIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OTITIS MEDIA; PAIN; PERCEPTION DEAFNESS; PERIPHERAL EDEMA; PHARYNGITIS; PHOTOTHERAPY; PNEUMONIA; PREGNANCY; PSORIASIS; REVIEW; RHINITIS; SEPSIS; SINUSITIS; SKIN CANCER; SOLID TUMOR; SPONDYLITIS; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; VOMITING; HOSPITALIZATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 33644901293     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.197     Document Type: Review

References (18)

1. NO AUTHORS LISTED: RAPTIVA® (efalizumab) package insert. South San Francisco, CA: Genentech, Inc. (2005).
2. LEBWOHL M, TYRING SK, HAMILTON TK et al.; EFALIZUMAB STUDY GROUP: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349:2004-2013.
3. MENTER A, GORDON K, CAREY W et al.; Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. (2005) 141:31-38.
4. GORDON KB, PAPP KA, HAMILTON TK et al.; EFALIZUMAB STUDY GROUP: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 290:3073-3080. Erratum in: JAMA (2004) 291:1070.
5. GOTTLIEB AB, GORDON KB, LEBWOHL MG et al.; EFALIZUMAB STUDY GROUP: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. (2004) 3:614-624.
6. LEONARDI CL, PAPP KA, GORDON KB et al.; EFALIZUMAB STUDY GROUP: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol. (2005) 52:425-433.
7. GOTTLIEB AB, MILLER B, LOWE N et al.: Subcutaneously administered efalizumab (anti-CD 11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cutan. Med. Surg. (2003) 7:198-207.
8. GAUVREAU GM, BECKER AB, BOULET LP et al.: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. (2003) 112:331-338.
9. LEONARDI CL, GOFFE B, SOBELL J et al.: The safety of efalizumab in patients with moderate to severe plaque psoriasis: summary of clinical trial experience. Presented at: 62ndAnnual Meeting of the American Academy of Dermatology, Washington, DC (2004). Poster 613.
10. MORSE LG, YARBROUGH L, HOGAN DJ: Cervical cancer in a woman associated with long-term efalizumab therapy. J. Am. Acad. Dermatol. (2005) 53:354-355.
11. CATHER JC, MENTER A, VUGMEYSTER Y et al.: Efalizumab (anti-CD11a)-induced increase in leukocyte numbers in psoriasis patients is preferentially mediated by blocked entry of memory CD8+ T cells into the skin. Clin. Immunol. (2004) 113:38-46.
12. GAYLOR ML, DUVIC M: Generalized pustular psoriasis following withdrawal of efalizumab. J. Drugs Dermatol. (2004) 3:77-79.
13. LOWES MA, TURTON JA, KRUEGER JC, BARNETSON RS: Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. (2005) 5:9.
14. TURNER J: Efficacy and safety of efalizumab therapy in two pediatric patients with plaque psoriasis Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2747.
15. GOTTLIEB A, LIZZUL P: Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis. Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2791.
16. HAMILTON TK: Clinical considerations of efalizumab therapy in patients with psoriasis. Semin. Cutan. Med. Surg. (2005) 24:19-27.
17. CATHER J, MENTER A, YOUNG M, WIATROWSKI M: The use of efalizumab in the clinic. Presented at: 63nd Annual Meeting of the American Academy of Dermatology, Washington, DC (2005). Poster 2810.
18. MORTENSEN DL, WALICKE PA, WANG X et al.: Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J. Clin. Pharmacol. (2005) 45:286-298.